Loading
A phase 3 trial of Melphalan flufenamide, Pomalidomide and Dexamethasone in Multiple myeloma, run by Oncopeptides AB, recorded as terminated on the registry.
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide is a phase 3 interventional study registered as NCT03151811 by Oncopeptides AB, with 495 participants recorded, started 2017-06-12 and due to reach its primary completion in 2021-02-03. Interventions recorded: Melflufen, Pomalidomide, Dexamethasone. Conditions recorded: Multiple Myeloma.
Linked to the drug Melphalan flufenamide because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
495 enrolled.
95% CI 4.96 to 8.54; Figures from the ClinicalTrials.gov results section (first posted 2022-07-27), not from a publication · 95% CI 4.24 to 5.72
Source95% CI 15.84 to 24.15; Figures from the ClinicalTrials.gov results section (first posted 2022-07-27), not from a publication · 95% CI 18.92 to 27.86
SourceFigures from the ClinicalTrials.gov results section (first posted 2022-07-27), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS)primary | Arm A: Melflufen+Dexamethasone | 246 | 6.83 months | - | 0.0311 | link |
| Arm B: Pomalidomide+Dexamethasone | 249 | 4.93 months | ||||
| Overall Survival (OS) | Arm A: Melflufen+Dexamethasone | 246 | 20.24 months | - | - | link |
| Arm B: Pomalidomide+Dexamethasone | 249 | 23.98 months | ||||
| Overall Response Rate (ORR) | Arm A: Melflufen+Dexamethasone | 246 | 80 participants | - | - | link |
| Arm B: Pomalidomide+Dexamethasone | 249 | 67 participants |
Shares Oncopeptides, Melphalan flufenamide, Dexamethasone, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Oncopeptides, Melphalan flufenamide, Dexamethasone, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Pomalidomide, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.